AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) Enhertu in combination with pertuzumab has been approved in the U.S. for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, as determined by a Food and Drug Administration-approved test, the company confirmed.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- FDA approves Enhertu with pertuzumab for certain HER2-positive breast cancer
- AstraZeneca’s Latest Study on AZD1613: A Potential Breakthrough for Kidney Disease
- AstraZeneca’s AZD4604: Promising Results in Asthma Treatment Study
- AstraZeneca’s AZD4076: Promising Developments in NASH Treatment
- AstraZeneca’s Acalabrutinib Study: A Potential Game-Changer for CLL Treatment